Development of Redox Controlling Nanomedicine Based on Albumin Fusion

基于白蛋白融合的氧化还原控制纳米药物的开发

• 批准号: 21390177
• 负责人: OTAGIRI Masaki
• 金额: $ 12.23万
• 依托单位: Sojo University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21390177/
• 关键词: ドラッグデリバリー; ヒト血清アルブミン; Thioredoxin 1; Pichia酵母; 肺障害; 抗酸化能; 酸化ストレス; Thioredexin 1; ドラッグデリバリー; ヒト血清アルブミン; Thioredoxin 1; Pichia酵母; 肺障害; 抗酸化能; 酸化ストレス; Thioredexin 1

Using albumin fusion technology, a novel redox controlling nanomedicine was designed and evaluated for applications in clinical settings. The results from various studies suggested that HSA-thioredoxin fusion protein has great potential as a therapeutic agent for treating oxidative stress and inflammation related diseases. In addition, a significant tumor metastasis activity from the EPR effect of SNO-HSA dimer has been confirmed. Based on the results of the current studies, preparations for a clinical trial led by a clinician are now in progress.

使用白蛋白融合技术，设计和评估了一种新型的氧化还原控制纳米医学，以适用于临床环境中的应用。各种研究的结果表明，HSA-硫蛋白融合蛋白作为治疗氧化应激和炎症相关疾病的治疗剂具有巨大潜力。此外，已经证实了SNO-HSA二聚体EPR效应的显着肿瘤转移活性。根据当前研究的结果，现在正在进行临床医生领导的临床试验的准备。